Zoetis (ZTS) Financials, Dividends & Stock Info
Explore comprehensive financial data for Zoetis, provided completely free. Analyze revenue, net income, profit margins, dividend history, and key financial ratios to make informed investment decisions.
Data as of (572 days ago)|Source: SEC EDGAR
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
Zoetis (ZTS) is a pharmaceuticals company. The company reports annual revenue of $9.4B and net income of $2.7B. Its profit margin is 28.2%.
Zoetis Key Financials(TTM Est.)
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Zoetis Financial Health ScoreFY2025
Moderate health; several metrics need attention
-16 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Strong profit margin: 28.2%
- Strong return on equity: 49.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Zoetis Recent Events
Source: SEC EDGAR 8-K Filings
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Revenue Breakdown (FY2024)
See Zoetis detailed breakdown →Showing top 3 of 4 segments
About Zoetis
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. Contemporaneous with the spinoff in June 2013 S&P Dow Jones Indices announced that Zoetis would replace First Horizon National Corporation in the S&P 500 stock market index.
- Industry
- Pharmaceuticals
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Above-Average Marginsvs 28.5% sector median / 26.8% avg
Generates $49.1 in profit for every $100 of shareholder equity. Higher than 73% in Health Care.
vs 7.2% sector median / 5.9% avg
Keeps 28 cents of every dollar in revenue as profit. Higher than 86% in Health Care.
5th consecutive year of revenue growth.
* Some quarterly data is missing. Values are calculated based on annual report figures.
Profit margin 378% above sector average.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Above-Average Leveragevs 1.31 sector median / 1.98 avg
Carries $1.31 in debt for every $1 of equity. Lower debt than 55% in Health Care. Debt has increased over the past 5 years.
Debt-to-equity ratio of 1.31 is above 1.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Zoetis 10-Year Revenue, Profit & Cash Flow History
Net income reached a record high of $2.7B in FY2025.
Annual Financials
FY2025 - FY2016| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.5B(+2.3%) | $9.3B(+19.0%) | $7.8B(+16.5%) | $6.7B(+6.6%) | $6.3B(+7.5%) | $5.8B(-6.9%) | $6.3B(+7.5%) | $5.8B(+22.2%) | $4.8B(-0.4%) | $4.8B(+4.9%) |
| Net Income | $2.7B(+7.5%) | $2.5B(+22.0%) | $2.0B(+24.4%) | $1.6B(+9.2%) | $1.5B(+5.0%) | $1.4B(-4.8%) | $1.5B(+5.0%) | $1.4B(+321.2%) | $339.0M(-41.9%) | $583.0M(+15.7%) |
| Total Assets | $15.5B | $14.2B | $14.3B | $14.9B | $13.9B | $13.6B | $11.5B | $10.8B | $8.6B | $7.6B |
| Total Debt | $9.0B | $5.2B | $6.6B | $6.6B | $6.6B | $6.6B | $5.9B | $6.4B | $5.0B | $4.5B |
| Total Equity | $3.3B | $4.8B | $5.0B | $4.4B | $4.5B | $3.8B | $2.7B | $2.2B | $1.8B | $1.5B |
| Profit Margin | 28.2% | 26.9% | 26.2% | 24.5% | 24.0% | 24.5% | 24.0% | 24.5% | 7.1% | 12.2% |
| ROE | 80.3% | 52.1% | 40.8% | 37.2% | 33.0% | 37.9% | 55.4% | 65.3% | 19.1% | 39.2% |
| ROA | 17.3% | 17.5% | 14.3% | 11.0% | 10.8% | 10.5% | 13.0% | 13.3% | 4.0% | 7.6% |
Quarterly Financials
Last 8 quarters| Metric | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2B | $6.9B | $4.6B | $2.2B | $6.3B | $4.2B | $2.0B | $6.0B |
| Net Income | $602.0M | $1.9B | $1.2B | $599.0M | $1.8B | $1.2B | $552.0M | $1.7B |
| Total Assets | $15.5B | $14.2B | $14.2B | $14.2B | $14.3B | $14.3B | $14.3B | $14.9B |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
3 insiders purchased shares worth $886K within a 30-day window — the most recent purchase was 22 days ago. Revenue grew +2.3% YoY and profit margin at 28.2%. Cluster buy signal strength: 45/100.
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Zoetis Dividend Safety Analysis & Growth History
Dividend Status
Dividend PayerThis company pays dividends. Historical dividend data shown below.
12 consecutive years of dividend increases. 5-year dividend CAGR: +20.1%.
Annual Dividends
2016 - 2025| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend/Share | $0.10 | $0.10 | $0.25 | $0.33 | $0.40 | $0.50 | $0.65 | $0.75 | $0.86 | $1.00 |
| YoY Growth | +14.5% | +10.5% | +140.0% | +30.2% | +21.9% | +25.0% | +30.0% | +15.4% | +15.2% | +15.7% |
| Payments | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Increased | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Learn more: Dividend investing guide | How to evaluate dividend safety
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Zoetis Free Cash Flow & Dividend Coverage
Generates approximately $6M in free cash flow per day.
Cash Flow History
FY2016 - FY2025| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | $626.0M | $664.0M | $1.8B | $1.8B | $1.8B | $1.8B | $2.1B | $2.2B | $3.0B | $2.9B |
| CapEx | -$180.0M | -$224.0M | -$338.0M | -$460.0M | -$338.0M | -$460.0M | -$453.0M | -$477.0M | -$655.0M | -$621.0M |
| Free Cash Flow | $446.0M | $440.0M | $1.5B | $1.3B | $1.5B | $1.3B | $1.7B | $1.7B | $2.3B | $2.3B |
| FCF Margin | 9.3% | 9.2% | 24.9% | 21.3% | 24.9% | 21.3% | 25.1% | 22.3% | 24.8% | 24.1% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Zoetis Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for ZTS.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Zoetis FAQ
What is Zoetis's annual revenue?
Zoetis (ZTS) reported $9.4 billion in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Is Zoetis profitable?
Yes, Zoetis is profitable with a 28.2% net profit margin and $2.7 billion in net income (TTM). All figures from SEC EDGAR 10-K filings.
Does Zoetis pay dividends?
Yes, Zoetis pays regular dividends with 12 consecutive years of dividend payments. View the full dividend history and payout analysis on this page.
What is Zoetis's financial health score?
Zoetis has a financial health score of 69/100 (Grade: C), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Zoetis financial data are available?
10 years of financial data are available for Zoetis from FY2016 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.